Militia Capital Partners’s AbbVie ABBV Stock Holding History

Militia Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$274K	Buy	+1,200	New	+$273K	0.06%	187

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Militia Capital Partners's ABBV Position: Q4 2025 in Review

Militia Capital Partners opened a new position in AbbVie (ABBV) in Q4 2025: 1,200 shares worth $274K. The stake represents 0.06% of the portfolio and ranks #187 among its holdings.

4,164 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Militia Capital Partners held 1,200 shares of AbbVie worth $274K as of Q4 2025.
AbbVie was a new Militia Capital Partners position in Q4 2025.
AbbVie made up 0.06% of Militia Capital Partners's portfolio in Q4 2025, its #187 holding.
4,164 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.